Firma Immunic, Autor bei News-Research

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

3. August 2020 Firma ImmunicPosted in Forschung und EntwicklungTagged 4sc, altium, brain, fiscal, immunic, immunic's, imu, liver, market, patients, revenue, rrms, statements, syndrome, with

Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis Statistically Significant Reduction of 62% and 70% in Combined Unique Active […]

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

27. Juli 202013. Dezember 2023 Firma ImmunicPosted in AllgemeinTagged cancer, dosing, fiscal, immunic, immunic's, imu, market, nhs, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced enrollment of the first patients in […]

Immunic, Inc. to Join Russell 3000® Index

22. Juni 202013. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged colitis, cov, covid, fiscal, immunic, immunic's, imu, index, market, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

15. Juni 2020 Firma ImmunicPosted in Forschung und EntwicklungTagged calvid, colitis, dosing, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. Announces Proposed Public Offering of Common Stock

10. Juni 202013. Dezember 2023 Firma ImmunicPosted in FirmeninternTagged clinical, covid, fiscal, immunic, immunic's, imu, market, prospectus, revenue, roth, securities, statements, syndrome, treatment, with

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

9. Juni 202013. Dezember 2023 Firma ImmunicPosted in Forschung und EntwicklungTagged calvid, cells, colitis, fiscal, immunic, immunic's, imu, market, patients, revenue, securities, statements, syndrome, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced receipt of regulatory allowance from the […]